← FDA DRUG APPROVALS

FDA ANDA · ANDA202496

IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE

Sponsor: RITEDOSE CORP

APPLICATION
ANDA202496
TYPE
ANDA
ORIGINAL APPROVAL
2012-10-01
LATEST ACTION
2012-10-01
ROUTE
RESPIRATORY (INHALATION), INHALATION
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDEPrescription
ALBUTEROL SULFATE EQ 0.083% BASE, IPRATROPIUM BROMIDE 0.017% · SOLUTION · INHALATION

Approval history

2012-10-01UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →